Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ADV-TK Improves Outcome of Recurrent High-Grade Glioma (HGG-01)

This study has been completed.
Beijing Tiantan Hospital
Beijing Chao Yang Hospital
Beijing Friendship Hospital
Information provided by (Responsible Party):
Ding Ma, Huazhong University of Science and Technology Identifier:
First received: March 26, 2009
Last updated: June 22, 2013
Last verified: June 2013
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.

Condition Intervention Phase
Malignant Glioma of Brain
Biological: ADV-TK/GCV
Procedure: Surgery
Drug: systemic chemotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma

Resource links provided by NLM:

Further study details as provided by Huazhong University of Science and Technology:

Primary Outcome Measures:
  • The primary end point was 6-month progression-free survival rate (PFS-6) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • progression-free survival (PFS) [ Time Frame: 3 years ]
  • overall survival (OS) [ Time Frame: 3 years ]
  • safety [ Time Frame: 1. at the time during treatments; 2. at 6-month; 3. at the end of 1-year following-up; 4. at the end of 2-year following up; 5. at the time the patient censored. ]
  • clinical benefit [ Time Frame: at the end of 2nd ADK-TK/GCV therapy ]
    the rate of complete response, plus partial response, plus stable disease

Enrollment: 47
Study Start Date: January 2008
Study Completion Date: December 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADV-TK/GCV
ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
Biological: ADV-TK/GCV
gene therapy
Active Comparator: Control group
Patients received surgery or systemic chemotherapy or palliative care.
Procedure: Surgery Drug: systemic chemotherapy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed WHO grades 3 to 4 malignant glioma
  • Diagnosed recurrence or progression by clinical or radiological evidence
  • Fit for intraarterial infusion and intravenous chemotherapy
  • Adequate hepatic, renal, and hematologic function.
  • Legal age ≥18 years
  • Life expectancy ≥12 weeks
  • Eastern Cooperative Oncology Group performance (ECOG) ≥2
  • Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.

Exclusion Criteria:

  • Active pregnancy
  • Prior gene therapy
  • Second primary tumor
  • Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections
  • Requiring treatment with warfarin or any other anticoagulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00870181

China, Beijing
Beijing YouAn Hospital
Beijing, Beijing, China, 100069
Sponsors and Collaborators
Huazhong University of Science and Technology
Beijing Tiantan Hospital
Beijing Chao Yang Hospital
Beijing Friendship Hospital
Study Director: Ma Ding, M.D. Tongji Hospital of HUST
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ding Ma, Director of Department of Gynecology and Obstetrics, Huazhong University of Science and Technology Identifier: NCT00870181     History of Changes
Other Study ID Numbers: 2009HGG-01
Study First Received: March 26, 2009
Last Updated: June 22, 2013

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on May 22, 2017